BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

NEW YORK, April 11, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, “the Company”), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the “Notification Letter on Compliance”) on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), indicating that the Company has regained compliance with […]

April 11, 2024